Novacyt Group (/ˈnoʊvəsaɪt/ NOH-və-syte) is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France.

[1][2] The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide.

[3] Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.

[5][6][7][8] The test was approved as eligible for procurement under the World Health Organization's (WHO) Emergency Use Listing process in April 2020,[9] meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response.

[10] In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory.